{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:50:58Z","timestamp":1791996658273,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jbo.2026.100797","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:50Z","timestamp":1787008430000},"page":"100797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction"],"prefix":"10.1016","volume":"60","author":[{"given":"E.","family":"Massy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Stacoffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fauvernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lamkhioued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Domblides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stuani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Pialat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jbo.2026.100797_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziaf081","article-title":"Epidemiology of bone metastasis in France between 2009 and 2018","volume":"9","author":"Marchal","year":"2025","journal-title":"JBMR Plus."},{"key":"10.1016\/j.jbo.2026.100797_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bone.2018.01.004","article-title":"Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers","volume":"108","author":"Chambard","year":"2018","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jbo.2026.100797_bb0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2026.100797_bb0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol. Rev."},{"issue":"22","key":"10.1016\/j.jbo.2026.100797_bb0025","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2026.100797_bb0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jbo.2026.100797_bb0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \u201ccold\u201d immune characteristics in non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2026.100797_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J. Bone Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2026.100797_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.jbo.2026.100797_bb0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.6004\/jnccn.2020.7668","article-title":"Bone metastases, skeletal-related events, and survival in patients with metastatic non-small cell lung Cancer treated with immune checkpoint inhibitors","volume":"19","author":"Qin","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.jbo.2026.100797_bb0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.21873\/anticanres.14913","article-title":"Site-specific Response to Nivolumab in Renal Cell Carcinoma","volume":"41","author":"Negishi","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbo.2026.100797_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2022.12.028","article-title":"Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: results of the GETUG-AFU26-NIVOREN multicentre phase II study","volume":"182","author":"Velev","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.jbo.2026.100797_bb0065","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.3390\/biomedicines10112758","article-title":"Impact of bone metastases on patients with renal cell carcinoma or melanoma treated with Combotherapy Ipilimumab plus Nivolumab","volume":"10","author":"Pham","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.jbo.2026.100797_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071735","article-title":"Organ-specific and mixed responses to pembrolizumab in patients with unresectable or metastatic urothelial carcinoma: a multicenter retrospective study","volume":"14","author":"Shimizu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jbo.2026.100797_bb0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the Ipilimumab versus placebo following radiotherapy phase III trial in Postdocetaxel metastatic castration-resistant prostate Cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.jbo.2026.100797_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00018.2019","article-title":"Immunity, hypoxia, and metabolism-the m\u00e9nage \u00e0 trois of Cancer: implications for immunotherapy","volume":"100","author":"Riera-Domingo","year":"2020","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.jbo.2026.100797_bb0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"issue":"43","key":"10.1016\/j.jbo.2026.100797_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non\u2013small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"issue":"12","key":"10.1016\/j.jbo.2026.100797_bb0095","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2026.100797_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101224","article-title":"Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis","volume":"69","author":"Massy","year":"2025","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.jbo.2026.100797_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.jbo.2026.100797_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jbo.2026.100797_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107858","article-title":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","volume":"193","author":"Asano","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2026.100797_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100634","article-title":"Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases","volume":"48","author":"Mabrut","year":"2024","journal-title":"J. Bone Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2026.100797_bb0125","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2026.100797_bb0130","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung Cancer","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2026.100797_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.07.007","article-title":"CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases","author":"Shi","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbo.2026.100797_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.03.036","article-title":"Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts","author":"Cheng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbo.2026.100797_bb0145","article-title":"Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jbo.2026.100797_bb0150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2026.100797_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007310","article-title":"Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer","volume":"11","author":"Naqash","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2026.100797_bb0160","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Sig. Transduct. Target Ther."},{"issue":"7957","key":"10.1016\/j.jbo.2026.100797_bb0165","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"issue":"10459","key":"10.1016\/j.jbo.2026.100797_bb0170","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jbo.2026.100797_bb0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2026.100797_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2025-003173","article-title":"Denosumab usage is associated with better overall survival of patients with lung cancer and bone metastases: a retrospective cohort study","volume":"12","author":"Yu","year":"2025","journal-title":"BMJ Open Resp. Res."},{"key":"10.1016\/j.jbo.2026.100797_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107417","article-title":"High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors","volume":"186","author":"Manglaviti","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2026.100797_bb0190","article-title":"A multicenter phase 2 study evaluating Denosumab in combination with Nivolumab as second-line therapy for patients with stage IV non-small\u2013cell lung cancer with bone metastases, DENIVOS-GFPC 06-2017","author":"Decroisette","year":"2026","journal-title":"SSRN"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742600059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742600059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:31:17Z","timestamp":1791995477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213742600059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S221213742600059X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100797","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100797"}}